National Institutes of Health launch US clinical trial of XF-73, a new anti-Staphylococcal drug

Scientists have launched an early-stage clinical trial of a novel topical
antimicrobial compound known as XF-73 that has shown promise for eliminating
Staphylococcus aureus bacteria in the nose, a therapeutic approach that
reduces the risk of staph infections. The study is being sponsored by
the National Institute of Allergy and Infectious Diseases (NIAID), part
of the National Institutes of Health. Further details are provided here